Human blood is the source of a wide range of medicinal products used for the prevention and treatment of a variety of often life-threatening injuries and diseases. Over the past 2 decades, due to the establishment of the more sensitive methods being used to screen donated blood and plasma pools, and of manufacturing practices that lead to virus inactivation and removal the transmission of the principal viral threats, such as HIV, HBV and HCV, the risk has greatly reduced. However, the transmission of blood-borne viruses by blood, blood component, plasma and purified plasma products is still considered to constitute a risk to patients. The purpose of our studies is to reduce the risk of blood related infectious disease. The study contents including:

• Characterize and identify the molecular epidemiology of the agents of transfusion transmitted infectious disease; research and develop the methods to reduce the risk of transfusion transmitted infectious diseases by screening for the serological markers of infections, and nucleic acid testing (NAT) for sensitive detection of known, unknown, emerging and reemerging infectious agents.
• Research and development of the YWW007 (Methylene blue derivative ) pathogen reduction technology（YWW007 PRT） in blood components, plasma and plasma products and to establish the evaluation system, including, validation and assessment of the steps for viral inactivation and removal employed in blood components, the manufacture of human blood plasma derivatives and virally inactivated plasma for transfusion.
• To elucidate HIV-1 viral infection in HIV-1 viral life cycle, the HIV-1 glycoprotein mutants are utilized to show the majority functional positions during viral entry by structure-function analysis. The entry inhibitors, membrane fusion inhibitors and the reverse transcriptase inhibitors are considered as the detecting probes and tools in our research. Within this research, more details about viral infection and viral spread are expecting. More information of the HIV-1 drug treatment will be provided either.
• To conduct the Retrovirus Epidemiology Donor Study II International ( REDS-II International ) and REDS-III International projects. This study will improve our understanding of blood safety in China through epidemiologic, survey and laboratory studies designed to 1) evaluate and monitor the risks of the major TTVIs and their determinants;  2) assess donors’ demographics and donation patterns;  3) evaluate test performance and characterize viral dynamics in higher versus lower TTVI prevalence settings; and 4) evaluate TTVI risk factors and donors’ knowledge and attitudes to help improve behavioral screening. This study will contribute invaluable data and research findings and potentially significantly impact policy development with regards to infectious disease screening in China.